Categories
- ACTUARIAL DATA SCIENCE
- AFIR / ERM / RISK
- ASTIN / NON-LIFE
- BANKING / FINANCE
- DIVERSITY & INCLUSION
- EDUCATION
- HEALTH
- IACA / CONSULTING
- LIFE
- PENSIONS
- PROFESSIONALISM
- Thought Leadership
- MISC
Currently much attention is focused on SARS-CoV-2 and its implications on insurance business, economy and society. What is the current state of the art, what did we learn so far? Will we face in a foreseeable mid-term future another pandemic, possibly SARS-CoV3? What are the chances? Currently one key aspect is completely ignored in the context of the SARS-CoV-2 pandemic: numerous COVID-19 patients are treated blindly and on a large scale with antibiotics. So this approach increases significantly the risk of widespread antibiotic resistance, a "pandemic" of its own kind, as this does not affect only infectious diseases, but surgeries of all kind which will be more hazardous than currently.
0 Comments
There are no comments yet. Add a comment.